Latest news with #RickySun
Japan Times
09-02-2025
- Business
- Japan Times
Bain to acquire Mitsubishi Tanabe Pharma in $3.3 billion deal
Private equity firm Bain Capital agreed to acquire Mitsubishi Chemical Group's pharmaceutical unit, adding to a dealmaking boom in Japan. The deal values Mitsubishi Tanabe Pharma at about ¥510 billion ($3.3 billion), according to a statement on Friday. The transaction is expected to be completed in the third quarter, pending closing conditions and approvals from regulators and shareholders. In a separate statement, Mitsubishi Chemical said it expects to book pre-tax income from discontinued operations of about ¥95 billion. Founded in 1678 and based in the city of Osaka, Tanabe Pharma focuses on therapeutic areas such as immunology and inflammation, vaccines, diabetes, and central nervous system and metabolic disease. It employs more than 5,000 people globally. "We believe there are promising signs for growth and untapped opportunities in Japan's life sciences industry as government and regulators have launched several initiatives to accelerate the development and approval of innovative medicines,' said Ricky Sun, a Partner at Bain Capital Life Sciences. Tanabe Pharma will continue to build on its legacy of medical innovation while boosting growth via business development, licensing, and strategic acquisitions, among other options, according to the statement. Bain has been ramping up investment in Japan, a hive of dealmaking activity. The Boston-based firm is duking it out with KKR for Fuji Soft, with KKR once again raising its offer for the Japanese software company.
Yahoo
08-02-2025
- Business
- Yahoo
Bain Capital buys Mitsubishi Tanabe Pharma for $3.3bn
US private equity firm Bain Capital has agreed to acquire Mitsubishi Chemical Group's pharmaceutical unit Mitsubishi Tanabe Pharma in a deal valued at approximately Y510bn ($3.3bn). The transaction follows a sale process initiated by Mitsubishi Chemical Group in September 2024, as reported by Nikkei Asia. In the 7 February announcement, the parent company said that continuous additional investments are essential for enhancing R&D capabilities and achieving further growth. It added that Bain's expertise in healthcare investment was a key reason for its selection, offering Mitsubishi Tanabe 'multifaceted support from a new partner deeply knowledgeable in the pharmaceuticals business'. The deal is expected to close in Q3 2025. In December 2024, sources told Reuters that private equity firm Blackstone was also interested in a deal for Mitsubishi Tanabe along with Bain, valuing the company at between $3bn and $3.5bn. Bain life sciences partner Ricky Sun states that Japan's regulatory environment is evolving, with government initiatives aimed at accelerating drug development and approval: 'This is an exciting opportunity to leverage our team's clinical insights and company creation support to build out a scale platform focused on long-term fundamental drug development in areas of significant unmet need to ultimately bring transformative medicines to patients in Japan and globally.' Mitsubishi Tanabe, based in Osaka, Japan, develops treatments mainly for central nervous system disorders, immuno-inflammation, and oncology. The company has been expanding its pipeline with a number of deals over the last few years. In January 2025, Mitsubishi entered a licensing agreement with Lonza's subsidiary Synaffix to advance antibody-drug conjugate (ADC) programmes. Under the agreement, Synaffix will manufacture ADC-related components while Mitsubishi will oversee the research, development, and commercialisation of the programme. Financial terms for this agreement were not disclosed. In December 2024, Mitsubishi Tanabe Pharma announced a research collaboration with Boston, Massachusetts-based Dewpoint Therapeutics, with a deal valued for up to $480m. The partnership focuses on a preclinical amyotrophic lateral sclerosis (ALS) programme. Mitsubishi also has its own ALS treatment Radicava (edaravone), which was approved by the US Food and Drug Administration (FDA) in 2017. Other deals include one with Moderna for mRNA vaccines, and Eli Lilly Japan for the distribution and marketing of its GIP/GLP-1 receptor agonist blockbuster Mounjaro (tirzepatide). "Bain Capital buys Mitsubishi Tanabe Pharma for $3.3bn" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Zawya
07-02-2025
- Business
- Zawya
Bain to buy Japan's Mitsubishi Tanabe Pharma for $3.4bln
TOKYO - U.S. private equity firm Bain Capital has bought Mitsubishi Tanabe Pharma in a deal worth 510 billion yen ($3.4 billion), saying it was encouraged by prospects of regulatory change for Japan's drug industry. The Osaka-based firm has a pipeline of drugs relating to the central nervous system, immuno-inflammation and oncology. It has operations in more than a dozen locations across three continents outside Japan, according to its website. "We believe there are promising signs for growth and untapped opportunities in Japan's life sciences industry as government and regulators have launched several initiatives to accelerate the development and approval of innovative medicines in the Japanese market," Ricky Sun, partner at Bain Capital, said in a statement. Japanese health authorities have been looking at areas of reform, aware that many drugs developed in the United States and Europe have yet to be approved in Japan, in particular orphan and paediatric drugs. Bain is making the investment mainly via its Asia private equity fund with contributions from its global life sciences fund, said a person with knowledge of the transaction who declined to be identified as the information was not public. The seller, Mitsubishi Chemical, said it had made the sale as it was not in a position to provide the large-scale investment necessary to strengthen Mitsubishi Tanabe's research and development capacity. Proceeds from the sale will go towards investment in its core chemicals business as well as to help it reduce debt and enhance shareholder returns. Mitsubishi Tanabe saw core operating income slide 61% to 56.2 billion yen ($370 million) in the last financial year. Private equity-led buyouts are booming in Japan as companies increasingly carve out non-core businesses, under pressure from Japanese authorities to raise corporate and shareholder value. Bain and other foreign funds have ramped up acquisitions, helping propel inbound M&A in Japan to the top of the leaderboard in Asia in 2024 for the first time since 1999. ($1 = 151.8400 yen)
